0001140361-24-016120.txt : 20240328 0001140361-24-016120.hdr.sgml : 20240328 20240328160636 ACCESSION NUMBER: 0001140361-24-016120 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240328 DATE AS OF CHANGE: 20240328 EFFECTIVENESS DATE: 20240328 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Karuna Therapeutics, Inc. CENTRAL INDEX KEY: 0001771917 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 270605902 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 001-38958 FILM NUMBER: 24798859 BUSINESS ADDRESS: STREET 1: 99 HIGH STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 857-449-2244 MAIL ADDRESS: STREET 1: 99 HIGH STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 15-12G 1 ef20025061_15-12g.htm 15-12G
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 15

 
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
Commission File Number:  001-38958
 

Karuna Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
 

99 High Street, Floor 26
Boston, Massachusetts 02110
(857) 449-2244
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
 
Common Stock, par value $0.0001 per share
(Title of each class of securities covered by this Form)
 
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)


Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
 
 
Rule 12g-4(a)(1)
 ☒
 
Rule 12g-4(a)(2)
 ☐
 
Rule 12h-3(b)(1)(i)
 ☒
 
Rule 12h-3(b)(1)(ii)
 ☐
 
Rule 15d-6
 ☐
 
Rule 15d-22(b)
 ☐

Approximate number of holders of record as of the certification or notice date: One (1)*
 
Pursuant to the requirements of the Securities Exchange Act of 1934, Karuna Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
 
 
KARUNA THERAPEUTICS, INC.
     
Date:  March 28, 2024
By:
/s/ Kimberly M. Jablonski
  
    Name:
Kimberly M. Jablonski

  Title:
Vice President and Secretary